BioTime, Inc. (NYSEAMERICAN:BTX) saw a large growth in short interest in the month of August. As of August 15th, there was short interest totalling 13,086,517 shares, a growth of 10.1% from the July 31st total of 11,888,187 shares. Approximately 10.4% of the company’s stock are short sold. Based on an average daily volume of 502,834 shares, the short-interest ratio is currently 26.0 days.
Separately, Zacks Investment Research upgraded BioTime from a “hold” rating to a “buy” rating and set a $2.50 price objective on the stock in a report on Wednesday, July 11th.
A number of institutional investors have recently added to or reduced their stakes in the business. Renaissance Technologies LLC increased its stake in shares of BioTime by 206.9% in the fourth quarter. Renaissance Technologies LLC now owns 1,197,800 shares of the biotechnology company’s stock valued at $2,575,000 after buying an additional 807,500 shares in the last quarter. Two Sigma Advisers LP increased its stake in shares of BioTime by 422.0% in the fourth quarter. Two Sigma Advisers LP now owns 90,053 shares of the biotechnology company’s stock valued at $194,000 after buying an additional 72,803 shares in the last quarter. Millennium Management LLC increased its stake in shares of BioTime by 938.4% in the fourth quarter. Millennium Management LLC now owns 150,721 shares of the biotechnology company’s stock valued at $324,000 after buying an additional 136,206 shares in the last quarter. Schwab Charles Investment Management Inc. increased its stake in shares of BioTime by 20.9% in the first quarter. Schwab Charles Investment Management Inc. now owns 173,856 shares of the biotechnology company’s stock valued at $468,000 after buying an additional 30,056 shares in the last quarter. Finally, Northern Trust Corp increased its stake in shares of BioTime by 5.2% in the first quarter. Northern Trust Corp now owns 966,448 shares of the biotechnology company’s stock valued at $2,600,000 after buying an additional 47,957 shares in the last quarter.
BTX stock traded up $0.06 during midday trading on Monday, hitting $2.31. 431,700 shares of the company traded hands, compared to its average volume of 476,991. BioTime has a twelve month low of $1.98 and a twelve month high of $3.16.
BioTime (NYSEAMERICAN:BTX) last posted its quarterly earnings data on Thursday, August 2nd. The biotechnology company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.03. The company had revenue of $2.55 million during the quarter, compared to analysts’ expectations of $0.33 million. BioTime had a return on equity of 30.68% and a net margin of 828.55%.
BioTime, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies primarily in the United States and Israel. The company’s lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; and Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy.
See Also: How to Invest in Marijuana Stocks
Receive News & Ratings for BioTime Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for BioTime and related companies with MarketBeat.com’s FREE daily email newsletter.